Updates are available Correction dated 2025-01-15

Article History

Received: 25 October 2023

Accepted: 7 October 2024

First Online: 25 November 2024

Change Date: 15 January 2025

Change Type: Update

Change Details: The original version of the Transparent Peer Review File associated with this Article was updated shortly after publication to correct an error on page 21 wherein “Reduction: 64.7% [46.5–80.3] (22/34)” was incorrectly presented as “Reduction: 64.7% [45.6–80.3] (22/34)”.

Change Date: 15 January 2025

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1038/s41467-025-56170-9

Competing interests

: The authors declare the following competing interests: S.S. provided medical writing support to Daiichi Sankyo on this manuscript. In the past 36 months, he received payment for participating on data safety monitoring boards or advisory boards for Agenus, AstraZeneca, Bayer, BMS, CheckmAb, Daiichi Sankyo, GSK, Guardant Health, Merck, Novartis, Pierre-Fabre, Roche Genentech, Seagen, and T-One Therapeutics. K.R. provided research support to Daiichi Sankyo for this study. In the past 36 months, he received grants or contracts from Bayer, Merck, Guardant, Hibercell, Daiichi Sankyo, and Seagen; received payments for educational events from Daiichi Sankyo, Bayer, and Seagen; and received payment for participating on data safety monitoring boards or advisory boards from Seagen and Merck. T.M. received grants or contracts in the past 36 months from Amgen, Boehringer Ingelheim, Cimic Shift Zero, Daiichi Sankyo, Merck, Novartis, ONO Pharmaceutical, Pfizer, Syneos Health Clinical, and Eli Lilly and received payments for educational events from Bayer, Bristol Myers Squibb, Chugai, Daiichi Sankyo, Lilly Japan, Merck BioPharma, ONO Pharmaceutical, Sanofi, Taiho, Takeda, and Yakult Honsha. K.Y. reports support from Daiichi Sankyo for the present manuscript, grants from Taiho Pharmaceutical, and payment or honoraria from Daiichi Sankyo Co. Ltd, Chugai Pharmaceutical Co. Ltd, Bristol Myers Squibb, Eli Lilly Japan, Taiho Pharmaceutical Co. Ltd, Ono Pharmaceutical Co. Ltd, Takeda Pharmaceutical Co. Ltd, and Merck Biopharm Co. Ltd. T.N. received honoraria for lectures from Bristol Myers Squibb, Chugai Pharmaceutical, Daiichi Sankyo Pharmaceutical, Eli Lilly Japan, Merck Serono Pharmaceutical, Ono Pharmaceutical, Takeda Pharmaceutical, Taiho Pharmaceutical, and Yakult-Honsha and was a Data Safety Monitoring Board member for Janssen Pharmaceutical. E.E. received consultancy fees from Amgen, Bayer, Hoffmann-La Roche, Merck Serono, MSD, Novartis, Organon, Pierre Fabre, Sanofi, and Servier; received payments for educational events from Amgen, Bayer, Hoffmann-La Roche, Merck Serono, MSD, Novartis, Organon, Pierre Fabre, Sanofi, and Servier; and received payments for participating on advisory boards from Amgen, Bayer, Hoffmann-La Roche, Merck Serono, MSD, Novartis, Organon, Pierre Fabre, Sanofi, and Servier. J.R. reports no conflicts of interest. I.C. has been on advisory boards for Eli Lilly, Bristol Myers Squibb, MSD, Roche, Merck-Serono, AstraZeneca, OncXerna, Pierre Fabre, Boehringer Ingelheim, Incyte, Astellas, GlaxoSmithKline, Sotio, Eisai, Daiichi Sankyo, Taiho, Servier, Seagen, and Turning Point Therapeutics, reports research funding from Eli Lilly and Janssen Cilag, and honorarium from Eli Lilly, Eisai, Servier, Roche, BMS, and Novartis. M.D.B. reports no conflicts of interest. H.K. received grants or contracts in the past 36 months from Bristol Myers Squibb, Eisai Co. Ltd, Kobayashi Pharmaceutical, and Taiho Pharmaceutical; received consultancy fees from Daiichi Sankyo; received payments for educational events from Bayer Yakuhin, Bristol Myers Squibb, Chugai Pharmaceuticals, Daiichi Sankyo, Eli Lilly Japan, Merck Biopharma, MSD, ONO Pharmaceutical, Otsuka, Taiho Pharmaceutical Takeda, Teijin, and Yakult. F.S. reports no conflicts of interest. M.K. reports no conflicts of interest. K.I. is an employee of Daiichi Sankyo RD Novare, which is a subsidiary of Daiichi Sankyo. Y.K is an employee of and has stock options with Daiichi Sankyo. I.T. reports no conflicts of interest. D.B. reports no conflicts of interest. K.K. reports no conflicts of interest. A.G. reports consulting fees from Daiichi Sankyo, Bayer, Merck/MSD, Genentech/Roche, Natera, and BMS, payment/honoraria from Bayer, Genentech/Roche, and Merck/MSD, and participation on a data safety monitoring board or advisory board for Regeneron. T.Y. received grants or contracts from Amgen K.K., Chugai Pharmaceuticals, Daiichi Sankyo, Genomedia, MSD K.K., Nippon Boehringer Ingelheim, ONO Pharmaceutical, Parexel International, Pfizer Japan, Sanofi K.K., Sysmex, and Taiho and received payments for educational events from Bayer Yakuhin, Chugai, Eli Lilly Japan, Merck Biopharma, MSD, ONO Pharmaceutical, and Taiho.